Femeda
Femeda is a UK-based medical device company that develops and manufactures Pelviva, a single-use intra-vaginal device using proprietary Reactive Pulse Technology to treat female urinary incontinence. It serves women with bladder leakage via direct-to-consumer e-commerce, pharmacy retail, healthcare professional channels, and global licensing partnerships.
- Company typePrivate
- Founded2002
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Femeda does
Femeda Limited is a privately-held UK medical device company founded in 2002 and headquartered in Cramlington, Northumberland, with 11-50 employees. The company develops, manufactures, and commercialises Pelviva, a single-use, disposable intra-vaginal device that treats female urinary incontinence through its proprietary Reactive Pulse Technology (RPT) — an embedded microprocessor-controlled system that delivers reactive electrical pulses to stimulate and re-train pelvic floor muscles during 30-minute treatments. Clinical validation from a 12-week randomised study with 123 women showed 84% reported improved bladder control, and Pelviva is CE marked as a Class IIa medical device in Europe with initial positive FDA meetings completed. The IP portfolio comprises 26 granted global patents across four patent families extending to 2035, developed in partnership with Professor Jacqueline Oldham at Manchester University.
The business operates a hybrid go-to-market model: direct-to-consumer e-commerce via pelviva.com, pharmacy retail distribution, healthcare professional field sales in the UK, and a planned per-country global licensing model for international markets. Revenue is generated through hardware sales of the disposable device (a recurring-purchase consumable model) and prospective licensing royalties from distribution partners in the healthcare, pharmacy, and pharmaceutical sectors. Femeda owns its manufacturing facility in Cramlington, established in 2016, providing vertical integration over production.
Femeda has raised approximately $9.3M across six disclosed funding rounds (2007-2016) from investors including Hotspur Capital, Northstar Ventures, Acceleris Capital, Enterprise Ventures, Rising Stars Growth Fund, and Stargate Capital Investment Group. The company has secured key strategic partnerships with Manchester University, Health Innovation Manchester, and NHS trusts in the Greater Manchester region, and has won industry recognition including the Bionow Product of the Year 2018 and Medilink Partnership with Academia Award 2019.
Femeda firmographics
Firmographics- Name
- Femeda
- Legal name
- Femeda Limited
- Website
- https://femeda.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Femeda is a UK-based medical device company that develops and manufactures Pelviva, a single-use intra-vaginal device using proprietary Reactive Pulse Technology to treat female urinary incontinence. It serves women with bladder leakage via direct-to-consumer e-commerce, pharmacy retail, healthcare professional channels, and global licensing partnerships.
- Ownership category
- akta.pro rank
Femeda industry classification
Industry- Product category
- Female Incontinence Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Urogynecology & Pelvic Reconstructive Surgery (Female Pelvic Medicine) (HLAKAJAE)
- akta.pro secondary industries
- Female Pelvic Medicine & Reconstructive Surgery (Urogynecology) (HLAKAOAC), Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies) (HSABAKAH), Incontinence & Bladder Leak Products (Feminine) (CRABAIAM)
Keywords
Where Femeda is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Femeda business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Direct Product Sales: Direct-to-consumer sales of Pelviva devices through e-commerce platform (www.pelviva.com) and selected pharmacies. Single-use disposable products requiring repeat purchases.
- Licensing Revenue: Global licensing and distribution opportunities offered to partners in healthcare, pharmacy, and pharmaceutical sectors. Per-country licensing model to scale the business globally.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Femeda product offering
Product offeringCore offering
Femeda develops, manufactures, and sells Pelviva, a single-use disposable intra-vaginal medical device that uses proprietary Reactive Pulse Technology (RPT) with an embedded microprocessor to stimulate and retrain pelvic floor muscles for the treatment of female urinary incontinence (stress and urge). Each 30-minute treatment delivers reactive pulses through body-responsive foam, automatically adjusting intensity to maintain therapeutic levels. The device is sold direct to consumers, through selected pharmacies, to healthcare professionals, and via global licensing partners.
Product overview
Femeda is a specialist UK-based medical device company focused on female urinary incontinence. The company's portfolio centers on a single core product: Pelviva, a pelvic floor muscle re-trainer that uses proprietary Reactive Pulse Technology (RPT). Pelviva is a single-use, disposable intra-vaginal device containing a microprocessor that delivers electrical stimulation to pelvic floor muscles, treating both stress and urgency urinary incontinence. The company operates its own manufacturing facility in Cramlington, UK (established 2016) and holds CE marking (Class IIa) for European commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- Pelviva Single-use, disposable intra-vaginal medical device that uses proprietary Reactive Pulse Technology (RPT) with an embedded microprocessor to stimulate and retrain pelvic floor muscles for the treatment of female urinary incontinence (stress and urge). Each 30-minute treatment delivers reactive pulses through body-responsive foam that adapts to the user's anatomy, automatically adjusting intensity to maintain therapeutic levels. Clinically proven in a 12-week, 123-woman study with 84% reporting improved bladder control and 4x greater reduction in impact vs. unsupervised pelvic floor exercises. CE marked (Class IIa) for European commercialisation. Sold to women with urinary incontinence via www.pelviva.com, selected UK pharmacies, and healthcare professional channels; available globally via licensing partners.
Quantifiable outcome
- 84% of women reported improved bladder control
- +2 more outcomes
Companies that use Femeda
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Femeda technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Femeda partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Professor Jacqueline Oldham / Manchester UniversitycoreCollaborative research partnership with Professor Jacqueline Oldham of Manchester University for development of Pelviva's Reactive Pulse Technology. Professor Oldham developed the programme of neuromuscular electrical stimulation used in the device. Partnership resulted in patents and clinical validation.
- Wellcome Trust Clinical Research Centre, ManchestercoreClinical study led by Professor Jackie Oldham and team at the Wellcome Trust Clinical Research Centre in Manchester conducted 12-week randomised single-blinded pre-post-test evaluation of Pelviva with 123 women, demonstrating proven efficacy.
- Health Innovation ManchestercorePartnership with Health Innovation Manchester and relevant NHS trusts to make Pelviva available to women in Greater Manchester region who have had limited alternatives for treatment of bladder leakage.
- Clinicians and Hospital Trusts (Greater Manchester)minorPartnership with clinicians and hospital trusts in the Manchester area who provided major support to bring Pelviva to market. Femeda is reinvesting by providing up to £50,000 of Pelviva product to women in the region via these clinical partners.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Femeda competitors and assessment
Company assessmentDirect peers
- Renovia: Developer of the Leva pelvic floor rehabilitation system, a prescription-connected device for female urinary incontinence. Comparable as an FDA-cleared, HCP-prescribed electrotherapeutic competitor in the US market Femeda is targeting.
- Perifit: Connected biofeedback pelvic floor trainer with app-based programmes for urinary incontinence and postpartum recovery. Competes with Pelviva for the same consumer segment, primarily through DTC e-commerce channels.
- InControl Medical: Manufacturer of the Apex pelvic floor muscle stimulator for bladder leakage. Closely comparable to Pelviva as a clinical/consumer electrostimulation device targeting stress and urge incontinence.
- Elvie (Chiaro Technology): Maker of the Elvie Trainer, a connected biofeedback pelvic floor exerciser. Targets the same women-with-weak-pelvic-floor consumer segment via DTC and retail; competes on category mindshare and shelf space with Pelviva.
- Atlantic Therapeutics: Developer of INNOVO, a non-invasive electrical muscle stimulator for pelvic floor strengthening and urinary incontinence. Directly comparable to Pelviva as a competing electrotherapeutic medical device for female UI, with similar regulatory and clinical positioning.
Emerging players
- Cognita Labs / ActivLife: Connected pelvic floor exercise device marketed to women for stress incontinence. Competes for the same consumer segment via app-connected training but with a different delivery model than Femeda's intra-vaginal device.
- TensCare: UK-based manufacturer of TENS/EMS devices for pain relief and pelvic floor stimulation. Competes in overlapping electrotherapy technology and UK distribution channels but is broader in therapeutic focus than Femeda's UI-specific positioning.
Broad incumbents
- Laborie Medical Technologies: Established player in urology and urogynecology diagnostics and therapeutics. Comparable as a large incumbent operating in female pelvic health that could be a strategic acquirer or licensing partner for Pelviva.
- CooperSurgical: Large women's health medical device company with broad OB/GYN and urogynecology portfolio. Comparable as a potential distribution/licensing partner and strategic acquirer in the female pelvic health category.
- Bioness (now Bioventus): Developer of electrotherapy and neuromuscular stimulation devices across rehabilitation indications. Comparable as a larger incumbent with overlapping electrotherapeutic technology for pelvic floor and incontinence applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
Femeda social profiles
Digital presenceFemeda compliance and trust
Trust signalCompliance1 record
Femeda financial estimates
Financial estimateRevenue estimate
Valuation estimate
Femeda leadership team
Management profileNumber of profiles
Profiles1 record
Femeda funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Femeda M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Femeda
What does Femeda do?
Femeda develops, manufactures, and sells Pelviva, a single-use disposable intra-vaginal medical device that uses proprietary Reactive Pulse Technology (RPT) with an embedded microprocessor to stimulate and retrain pelvic floor muscles for the treatment of female urinary incontinence (stress and urge). Each 30-minute treatment delivers reactive pulses through body-responsive foam, automatically adjusting intensity to maintain therapeutic levels. The device is sold direct to consumers, through selected pharmacies, to healthcare professionals, and via global licensing partners.
Is Femeda a public or private company?
Femeda is a private company. It is classified as venture growth investor backed and is currently operating.
When was Femeda founded?
Femeda was founded in 2002. It employs 11 to 50 people.
Where is Femeda based?
Femeda is headquartered in London, United Kingdom, in the Europe region.
How does Femeda make money?
Two revenue lines are on record. Direct Product Sales are the primary driver. The others are licensing Revenue.
Who are Femeda's main competitors?
Direct peers on record are Renovia, Perifit, InControl Medical, Elvie (Chiaro Technology) and Atlantic Therapeutics. Emerging players are Cognita Labs / ActivLife and TensCare. Broad incumbents are Laborie Medical Technologies, CooperSurgical and Bioness (now Bioventus).
Does Femeda have an API?
No public API is recorded for Femeda.
What industry is Femeda in?
Femeda's product category is Female Incontinence Medical Devices. Its primary akta.pro industry code is HLAKAJAE, Urogynecology & Pelvic Reconstructive Surgery (Female Pelvic Medicine), with a secondary code of HLAKAOAC, Female Pelvic Medicine & Reconstructive Surgery (Urogynecology). Its NAICS code is 334510 and its SIC code is 3845.